Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

OmniComm Systems, Inc. Reports Financial Results f

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 112)
Posted On: 03/30/2017 2:00:20 PM
Avatar
Posted By: News Desk 2018
OmniComm Systems, Inc. Reports Financial Results for the Year Ended December 31, 2016

FORT LAUDERDALE, FL, March 30, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced record financial results for the year ended December 31, 2016.

“The year of 2016 has been another record-breaking year in a string of very successful years,” said Stephen Johnson, OmniComm’s president and chief operating officer. “The strength of our product lines, our commitment to innovation and excellent customer service continue to propel our company forward. Our business in international markets continues to expand and our core product line, TrialMaster®, saw record contract and revenue results across all four quarters in both repeat and new business. This is a testament to the hard work our people have put into this company and to the loyal support our customers have given us.  We are excited about our future prospects and look forward to delivering more innovative solutions that ultimately help improve patient quality of life and outcomes.”

For the year ending December 31, 2016, OmniComm reported record revenue of $25.4 million, a 23% increase over the prior year’s revenue of $20.7 million. Gross margin improved by 23% or $3.8 million to $20.0 million.  Operating expenses increased by 6% or $0.9 million to $15.9 million, which resulted in operating income of $4.2 million, a 233% increase over 2015 operating income results. EBITDA, a non-GAAP financial measure OmniComm uses as an additional financial measure, improved by $3.0 million or 195% to $4.5 million.

“I am extremely pleased with our 2016 financial results,” said Cornelis Wit, OmniComm’s chief executive officer. “These strong results, with significant improvements in both top-line revenue and operating income, clearly demonstrate OmniComm’s ability to provide the life sciences sector with products and services that improve the clinical trial process.”

OmniComm provides EBITDA, a non-GAAP financial measure as additional information to its financial results.  Non-GAAP EBITDA excludes the impact of depreciation and amortization expenses that are included in operating income. Non-GAAP EBITDA is not an alternative or substitute for the financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) of operating income. The non-GAAP EBITDA financial measure presented may differ from similarly titled non-GAAP financial measures presented by other companies, and other companies may not define this non-GAAP financial measure in the same way. OmniComm’s management uses non-GAAP EBITDA as a measure of operational efficiency and as a goal for incentive compensation.  Management believes non-GAAP EBITDA is a useful measure investors may use as an additional factor in their analysis of OmniComm’s performance. Please review the below reconciliation of the non-GAAP financial measure EBITDA to the GAAP financial measure operating income, as well as OmniComm’s financial statements as filed with the Securities and Exchange Commission.

   
  OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
  Reconciliation of GAAP operating income to non-GAAP EBITDA
             
        For the year ended
        December 31,
        2016   2015
  Operating income/(loss) (GAAP) 4,165,231   1,252,230
  Depreciation expense 302,893   233,798
  Amortization expense 37,331   40,338
  EBITDA (non-GAAP) 4,505,455   1,526,366
             

Forward-Looking Statements  Statements contained in this press release that are not historical facts are "forward-looking statements." These statements can often be identified by the use of forward-looking terminology such as "estimate," "project," "believe," "expect," "may," "will," "should," "intends," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements regarding matters that are not historical facts are only predictions and are based on information available at the time and/or management's good faith belief with respect to future events. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this press release. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward-looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. Forward-looking statements speak only as of the date the statement was made. OmniComm does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

   
  OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
  CONSOLIDATED STATEMENTS OF OPERATIONS
             
        For the year ended
        December 31,
          2016       2015  
  Revenues     $ 24,394,010     $ 20,023,733  
  Reimbursable revenues   1,025,500       687,104  
  Total revenues     25,419,510       20,710,837  
             
  Cost of goods sold   3,913,407       3,770,013  
  Reimbursable expenses-cost of goods sold   1,461,425       677,568  
  Total cost of sales   5,374,832       4,447,581  
             
  Gross margin     20,044,678       16,263,256  
             
  Operating expenses      
  Salaries, benefits and related taxes   11,383,727       10,602,686  
  Rent and occupancy expenses   1,071,363       972,862  
  Consulting services   185,340       253,626  
  Legal and professional fees   364,859       415,834  
  Travel       774,379       779,817  
  Telephone and internet   164,014       166,361  
  Selling, general and administrative   1,462,774       1,530,765  
  Bad debt expense   132,767       14,939  
  Depreciation expense   302,893       233,798  
  Amortization expense   37,331       40,338  
  Total operating expenses   15,879,447       15,011,026  
             
  Operating income/(loss)   4,165,231       1,252,230  
             
  Other income/(expense)      
  Interest expense, related parties   (918,189 )     (2,434,101 )
  Interest expense   (421,713 )     (299,668 )
  Interest income   2       4  
  Change in derivative liabilities   (2,657,910 )     4,525,798  
  Impairment of goodwill   -0 -     (536,285 )
  Other income     -0 -     124,373  
  Transaction gain/(loss)   (64,472 )     (70,706 )
  Income/(loss) before income taxes   102,949       2,561,645  
  Income tax (expense)   (1,069 )     24,739  
  Net income/(loss)   101,880       2,586,384  
  Preferred stock dividends      
  Preferred stock dividends in arrears      
  Series A preferred   -0 -     (181,886 )
  Total preferred stock dividends   -0 -     (181,886 )
                 
  Net income/(loss) attributable to common stockholders $ 101,880     $ 2,404,498  
             
  Net income/(loss) per share      
  Basic     $ 0.00     $ 0.02  
  Diluted   $ 0.00     $ 0.02  
  Weighted average number of shares outstanding      
  Basic       145,868,227       96,645,482  
  Diluted     146,162,427       113,545,741  
             

 

  OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
  CONSOLIDATED BALANCE SHEETS
               
          December 31, 2016   December 31, 2015
  ASSETS
               
  CURRENT ASSETS        
    Cash   $ 1,439,332     $ 835,219  
    Accounts receivable, net of allowance for doubtful accounts of $179,813 and $116,834, respectively     5,455,210       4,092,472  
    Prepaid expenses     195,915       170,173  
    Prepaid stock compensation, current portion     148,422       175,858  
    Other current assets     35,055       14,351  
      Total current assets     7,273,934       5,288,073  
    Property and equipment, net     637,552       683,712  
    Other assets        
    Intangible assets, net     108,880       148,877  
    Prepaid stock compensation     58,663       150,085  
    Other assets     51,321       46,565  
               
  TOTAL ASSETS   $ 8,130,350     $ 6,317,312  
               
  LIABILITIES AND SHAREHOLDERS' (DEFICIT)
  CURRENT LIABILITIES        
    Accounts payable and accrued expenses   $ 2,123,073     $ 1,957,270  
    Deferred revenue, current portion     7,250,061       7,054,614  
    Convertible notes payable, current portion     50,000       75,000  
    Patent settlement liability, current portion     862,500       962,500  
    Conversion feature liability, related parties     1,740,278       535,835  
    Conversion feature liability     585,452       365,408  
    Warrant liability, related parties     2,519,614       1,353,786  
    Warrant liability     1,479,748       561,137  
      Total current liabilities     16,610,726       12,865,550  
               
  LONG TERM LIABILITIES        
    Line of credit, long term     2,700,000       4,200,000  
    Notes payable, related parties, long term, net of current portion, net of discount of $237,664 and $-0-, respectively     212,336       20,000  
    Notes payable, long term, net of current portion, net of discount of $455,285 and  $-0-, respectively     337,215       792,500  
    Deferred revenue, long term, net of current portion     2,289,169       2,193,163  
    Convertible notes payable, related parties, long term, net of current portion     5,825,000       5,850,000  
    Convertible notes payable, long term, net of current portion     1,175,000       1,350,000  
    Patent settlement liability, long term, net of current portion     108,702       464,573  
               
  TOTAL LIABILITIES     29,258,148       27,735,786  
               
  COMMITMENTS AND CONTINGENCIES        
  SHAREHOLDERS' (DEFICIT)        
    Preferred stock, $0.001 par value, 10,000,000 shares authorized, 3,772,500 shares undesignated     -0 -     -0 -
    Series B convertible preferred stock, 230,000 shares authorized, -0- and -0-  issued and outstanding,                
      respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively     -0 -     -0 -
    Series C convertible preferred stock, 747,500 shares authorized, -0- and -0-  issued and outstanding,                
      respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively     -0 -     -0 -
    Series A convertible preferred stock, 5,000,000 shares authorized, -0- and 3,637,724 issued and outstanding,            
      respectively at $0.001 par value; liquidation preference $-0- and $3,637,724, respectively     -0 -     3,637  
    Series D preferred stock, 250,000 shares authorized, 250,000 and 250,000 issued and outstanding,        
      respectively at $0.001 par value     250       250  
    Common stock, 500,000,000 shares authorized, 147,786,917 and 131,703,577 issued and outstanding,        
      respectively at $0.001 par value     147,788       131,704  
    Additional paid in capital - preferred     999,750       4,230,792  
    Additional paid in capital - common     53,425,956       49,974,415  
    Accumulated other comprehensive (loss)     (410,505 )     (366,355 )
    Accumulated (deficit)     (75,291,037 )     (75,392,917 )
               
  TOTAL SHAREHOLDERS' (DEFICIT)     (21,127,798 )     (21,418,474 )
               
  TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT)   $ 8,130,350     $ 6,317,312  
               
  OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
  CONSOLIDATED STATEMENTS OF CASH FLOWS
   
          For the year ended
          December 31,
          2016     2015  
               
  CASH FLOWS FROM OPERATING ACTIVITIES        
  Net income/(loss) $ 101,880   $ 2,586,384  
  Adjustment to reconcile net income/(loss) to net cash provided by/(used in) operating activities        
    Change in derivative liabilities   2,657,910     (4,525,798 )
    Impairment of goodwill   -0 -   536,285  
    Interest expense from derivative instruments   158,068     611,089  
    Employee stock compensation   222,304     245,083  
    Provision for doubtful accounts   132,767     14,939  
    Depreciation and amortization   340,224     274,136  
    Changes in operating assets and liabilities        
      Accounts receivable   (1,495,505 )   (691,260 )
      Prepaid expenses   (25,742 )   57,909  
      Other current assets   (20,704 )   3,954  
      Other assets   (4,756 )   2,527  
      Accounts payable and accrued expenses   615,803     733,085  
      Patent settlement liability   (455,871 )   (205,252 )
      Deferred revenue   291,453     1,013,834  
  Net cash provided by/(used in) operating activities   2,517,831     656,915  
               
  CASH FLOWS FROM INVESTING ACTIVITIES        
    Purchase of property and equipment   (260,378 )   (450,707 )
  Net cash (used in) investing activities   (260,378 )   (450,707 )
               
  CASH FLOWS FROM FINANCING ACTIVITIES        
    Repayments of notes payable   (245,000 )   (75,000 )
    Proceeds/(repayments) from revolving line of credit   (1,500,000 )   200,000  
    Proceeds from exercise of stock options   129,500     27,250  
  Net cash provided by/(used in) financing activities   (1,615,500 )   152,250  
               
  Effect of exchange rate changes on fixed and intangible assets   6,310     76,375  
  Effect of exchange rate changes on cash and cash equivalents   (44,150 )   (122,528 )
  Net increase/(decrease) in cash and cash equivalents   604,113     312,305  
  Cash and cash equivalents at beginning of period   835,219     522,914  
               
  Cash and cash equivalents at end of period $ 1,439,332   $ 835,219  
               

About OmniComm Systems, Inc.  OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 5,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. For more information, visit: www.omnicomm.com

Trademarks OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners. 

Contact Info Investor Relations OmniComm Systems, Inc. +1.954.473.1254 invrel@omnicomm.com



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us